In this special episode on SGLT-2 inhibitors and CKD Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in decreasing progression of chronic kidney disease.    This special episide is supported by independent educational grant from AstraZeneca. For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Background, Epidemiology, and Pathophysiology of Diabetic Kidney Disease ADA Recommendations for Screening and Diagnosis of Diabetic Kidney Disease ADA Recommendations for Treatment of CKD in Persons with Diabetes Review of the Literature SGLT-2 inhibitor effects on CV and Kidney Outcomes in Patients with T2DM Dapagliflozin in Patients with Chronic Kidney Disease CKD Testing in Patients with T2DM Second-Line Therapy for T2DM Management: The Treatment/Benefit Paradox of CV and Kidney Comorbidities eGFR dip After Starting SGLT-2 inhibitors Dapagliflozin in patients with T2DM and Stages 3b–4 chronic kidney disease Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health